The Giovanna Joyce Imbesi Above & Beyond Award The Giovanna Joyce Imbesi Above & Beyond Award is given to individuals in recognition of outstanding dedication to NET patient advocacy. Recipients of this award demonstrate an attitude of excellence, awareness, and hope for the neuroendocrine cancer community. The award is in honor of the late founder of LACNETS (now Neuroendocrine Cancer Foundation), Giovanna Joyce Imbesi . 2025 Awardee DUSTY HURLEY Watch the award presentation 2024 Awardee VAL TIPPY Watch the award presentation 2023 Awardee TOM BAJORAS Watch the award presentation 2022 Awardee MICHEL DEQUEVEDO Watch the award presentation 2021 Awardee SAMUEL PRENTICE JR. Watch the award presentation 2020 Awardee MARY DONLEVY Watch the award presentaion 2019 Awardee BRENT CURRIE Watch the award presentation 2018 Awardee BETH DEBLASE Watch the award presentation

Wellness Coaching Interest Form This coaching is about wellness coaching and self-care. It does not involve navigation or NET-specific discussions. For NET-specific information and resources, visit our Resources Page . For NET support assistance, go to our Support Line .

Symptom Management < Back to Topics Play Video Play Video 01:24:02 Practical Tips in Managing Neuroendocrine Cancer Care • • Sep 29, 2026 ABOUT Join Taymeyah and Tiffany as they share important insights to help you spearhead your medical team and confidently navigate your healthcare. Gain practical logistics for managing the ongoing cycle of scans, lab work, and "ologist" appointments. Discover well-informed, real-world suggestions on finding and building strong partnerships with your providers and specialists. We hope this discussion empowers you to effectively and efficiently coordinate your care. Visit the event page at https://www.ncf.net/events/sep2026 Play Video Play Video 01:09:03 Episode 49: "Understanding Carcinoid Syndrome & GLP-1 Drugs in Neuroendocrine Tumors" - Dr. Dillon ABOUT THIS EPISODE Carcinoid syndrome can be confusing and often difficult to diagnose. In this episode, Dr. Joseph Dillon, Endocrinologist and Director of the University of Iowa Neuroendocrine Multidisciplinary Tumor Clinic, explains what carcinoid syndrome is, how it’s diagnosed, and the various ways it can be treated. He highlights key symptoms, testing, and treatment approaches—including somatostatin analogs and telotristat—and discusses how to distinguish carcinoid syndrome from other causes of diarrhea and flushing. In the second half of the episode, Dr. Dillon shares insights from his separate line of research on GLP-1 receptor agonist weight-loss drugs (such as Ozempic® and Mounjaro®) and their potential implications for neuroendocrine tumor patients. (Note: this topic is unrelated to carcinoid syndrome.) MEET DR. JOSEPH DILLON Dr. Dillon is a Professor of Medicine in the Division of Endocrinology at the University of Iowa Hospitals and Clinics. He directs the University of Iowa Neuroendocrine Multidisciplinary Tumor Clinic. This was the first and only US NET Clinic to be recognized as a Center of Excellence by the European NET Society. He is also the Director of the PheoPara Alliance Center of Excellence at University of Iowa. His clinical practice is entirely focused on the care of people with neuroendocrine tumors, both carcinoid type and paraganglioma. He has participated in clinical trials and publications related to diagnostic and therapeutic nuclear agents and drug therapies in this population. Prior to focusing on NET he made important discoveries in the field of GLP-1 which are now becoming of importance to NET patients taking popular weight loss drugs. TOP TEN QUESTIONS: 1. What is carcinoid syndrome? 2. Who is affected by carcinoid syndrome? How does someone know if they have carcinoid syndrome? 3. What are the tests for carcinoid syndrome? How is carcinoid syndrome distinguished from other causes of my symptoms? *Could the tests be negative but someone still have carcinoid syndrome? 4. Can someone have no evidence of neuroendocrine tumors and still have carcinoid syndrome? 5. For those who have carcinoid syndrome, what additional tests should they have? 6. Why should carcinoid syndrome be treated? What are the possible issues if it is not treated? 7. How is carcinoid syndrome treated? *What is on the horizon for carcinoid syndrome treatment? 8. Can carcinoid syndrome be prevented or detected early? 9. Is there anything people can do to prevent or lessen carcinoid syndrome symptoms? Are there any factors that worsen carcinoid syndrome such as age, weight or other diseases? 10. You recently published a study discussing possible risks of using certain weight loss drugs in people with neuroendocrine cancer. Could you tell us more about this study? What was the drug and what did you find? What does it mean? What do you want the NET patient community to understand about your recent findings? Visit https://www.ncf.net/podcast/49 for more information. Play Video Play Video 01:01:43 Episode 20 - Gastric NET, Gastrinomas & Zollinger-Ellison Syndrome (ZES) ABOUT THIS EPISODE Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. MEET THE SPEAKER David C. Metz, MD Professor of Medicine, Perelman School of Medicine Co-Director Emeritus, University of Pennsylvania Neuroendocrine Tumor Program After earning his MD from the University of the Witwatersrand's Medical School, Dr. Metz was a resident at both the Albert Einstein Medical Center and the Johannesburg General Hospital. He went on to complete fellowships at Georgetown University Hospital as well as the National Institutes of Health. Arriving at Penn Medicine in 1993, David Metz, MD, held a variety of leadership roles within the Department of Gastroenterology, including Co-Directorship of the Neuroendocrine Tumor Center and Penn NET Treatment Program. Dr. Metz was previously a staff fellow at the National Institutes of Health, where he performed basic research in pancreatic acinar cell secretion and clinical research in Zollinger-Ellison syndrome. While at Penn Medicine, he served as Chair of the North American Neuroendocrine Tumor Society (NANETS), as a member of the Liaison Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative), and on the Food and Drug Administration Gastrointestinal Drugs Advisory Committee, among other positions. Dr. Metz's clinical interests at Penn included Zollinger-Ellison syndrome and other acid-peptic conditions, Helicobacter pylori infection, non-steroidal anti-inflammatory drug gastropathy and the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. An investigator for a series of prominent clinical trials in all of these areas, Dr. Metz has published more than 200 articles on topics of clinical interest and research. He retired in July 2021 after 28 years at Penn Medicine. In 2021 Dr. Metz received the NANETS Lifetime Achievement Award that honors an individual who, over the course of their career, has provided outstanding contributions to neuroendocrine disease management through research, clinical practice or educational initiatives, as well as exceptional leadership in NANETS and dedication to its mission. TOP 10 QUESTIONS 1. What is Gastric NET? How is it found? What are the symptoms? How does it differ from “stomach cancer” or other types of NETs? 2. How is Gastric NET treated and how is it monitored? 3. What is a Gastrinoma? How and where is it found? Are Gastrinomas and Gastric NET the same thing? 4. How is a Gastrinoma treated? 5. How is a Gastrinoma monitored? - How often do you recommend Endoscopies or Gastrin level lab testing? - Does a high Gastrin level mean someone has a Gastrinoma or are there other causes? Can you have a high Gastrin level without having a gastrinoma? 6. What is Zollinger-Ellison Syndrome? How is it found? What are the common symptoms from ZES/functioning Gastrinomas? 7. How is Zollinger-Ellison Syndrome treated? How is Zollinger-Ellison Syndrome monitored? Does ZES put you at risk for other conditions/complications? 8. What is a common Proton Pump Inhibitor dose for someone with ZES? Is there a danger in taking PPIs for a long time or in high doses? 9. I’ve been told I have an ulcer? Am I at risk for cancer? 10. What are advances for gastric nets, gastrinomas or Z-E syndrome that we should be aware of or excited about? *Bonus question: What last words of hope would you like to leave the NET community with? For more resources and the transcript of this episode, visit https://www.lacnets.org/podcast20. Play Video Play Video 17:59 5. What Matters About Symptom Management • Vineeth Sukrithan, MD • Neuroendocrine Cancer Foundation "What Matters About Symptom Management" 2025 Neuroendocrine Cancer Foundation Annual Patient Conference Vineeth Sukrithan, MD Medical Oncologist Ohio State University Play Video Play Video 01:29:43 When Hormones Interfere With Quality of Life • Dr. Jaydira Del Rivero • NCF 2026 When hormones are out of balance, the symptoms can have a significant impact on quality of life for people living with neuroendocrine cancer. In this Neuroendocrine Cancer Foundation (NCF) educational webinar, Dr. Jaydira Del Rivero, medical oncologist at the National Cancer Institute, explores how hormone excess, hormone deficiencies, and cancer treatments can affect the endocrine system—and what patients and caregivers should know. Topics covered include: • How hormone excess and hormone deficiency can affect the body • Hormone-related symptoms associated with neuroendocrine tumors • Carcinoid syndrome vs. serotonin syndrome • How immunotherapy may affect the pituitary, thyroid, adrenal glands, and pancreas • Adrenal insufficiency and cortisol deficiency • Thyroid dysfunction associated with cancer therapies • Endocrine effects of tyrosine kinase inhibitors (TKIs) and somatostatin analogs • Changes in blood glucose and insulin production • Sex hormone changes during treatment • Flushing related to carcinoid syndrome and menopause • GLP-1 agonists in the setting of neuroendocrine tumors • Symptoms and patterns patients should discuss with their healthcare team • Warning signs that may require urgent medical attention The goal of this session is to help patients and caregivers recognize symptoms earlier, understand when hormone testing may be appropriate, and have more informed conversations with their oncology and endocrinology teams. This webinar is for educational purposes only and is not a substitute for medical advice. Please contact your healthcare team with questions about your individual diagnosis, symptoms, or treatment. Learn more about the Neuroendocrine Cancer Foundation and its educational and support resources through NCF. Visit the event page at https://www.ncf.net/events/aug2026. Play Video Play Video 20:32 13. Navigating Treatment Side Effects • Jason Starr, DO • Mayo Clinic • 2026 NCF Conference In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Jason Starr, medical oncologist at Mayo Clinic in Jacksonville, Florida, presents “Navigating Treatment Side Effects.” Dr. Starr discusses how patients and care teams can balance treatment effectiveness with quality of life when using therapies for neuroendocrine cancers. He emphasizes the importance of early communication with the medical team, recognizing side effects promptly, holding medication when appropriate, using acute care resources when needed, and adjusting doses to find the right balance for each patient. This presentation reviews potential side effects and management strategies for somatostatin analogs, Lutetium-177 dotatate/Lutathera, PRRT, everolimus/Afinitor, CAPTEM, capecitabine, temozolomide, and tyrosine kinase inhibitors such as sunitinib and cabozantinib. Topics include fatigue, diarrhea, nausea, injection site pain, exocrine pancreatic insufficiency, blood sugar changes, gallbladder issues, bone marrow suppression, mouth sores, skin rash, blood pressure changes, wound healing concerns, thyroid issues, and medication interactions. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026conference This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment. #NeuroendocrineCancer #NeuroendocrineTumors #NETCancer #NETs #TreatmentSideEffects #SideEffectManagement #PRRT #Lutathera #CAPTEM #Everolimus #Cabozantinib #SomatostatinAnalogs #MayoClinic #NCF #PatientConference Play Video Play Video 09:44 "Practical Tips For Patients Preparing For Chemotherapy" • Lisa Yen, NP, NBC-HWC NET caregiver Lisa Yen’s “show and tell” of tips, tricks, and items she and her husband found to be helpful when dealing with chemotherapy. Read LACNETS blogpost Practical Tips For Patients Preparing For Chemotherapy: https://www.lacnets.org/post/practical-tips-for-patients-preparing-for-chemotherapy. For more information on LACNETS, visit www.LACNETS.org. Play Video Play Video 06:36 "Practical Tips for Cabozantinib" with Lisa Yen Starting a new cancer treatment can feel overwhelming—but you don’t have to navigate it alone. In this video, Lisa Yen, Director of Programs and Outreach at the Neuroendocrine Cancer Foundation, shares practical tips and real-life insights for patients preparing to take Cabozantinib (Cabometyx). Drawing from both her professional experience and her personal journey supporting her husband with a neuroendocrine tumor, Lisa walks through what to expect, how to prepare, and how to manage common side effects. You’ll learn about: Key resources, including oncology pharmacists and free patient care kits What’s included in the Cabometyx care kit and how it can help Common side effects like nausea, diarrhea, hand-foot syndrome, and high blood pressure Tips for tracking symptoms and staying organized with a treatment journal How and when to take Cabozantinib safely The importance of communication with your healthcare team This video is designed to help reduce uncertainty and empower patients and caregivers with actionable, experience-based guidance. 💡 Whether you’re just starting Cabozantinib or supporting someone who is, these tips can help you feel more prepared and confident in your treatment journey. Disclaimer: Always consult your healthcare team with any questions or concerns about your care. This content is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Play Video Play Video 01:37:36 "The Latest in the Management of Functional Neuroendocrine Cancers • Jan, 2026 • Dr. Del Rivero Join this @NCFCancer educational patient event for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), and other hormone-related issues. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. Potential Topics: Functional NET, Hormone-producing, Insulinoma, Gastrinoma, VIPoma, Zollinger-Ellison syndrome (ZES), Carcinoid, Hypoglycemia, Diarrhea, Flushing ABOUT DR. JAYDIRA DEL RIVERO Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. For more information, visit https://www.ncf.net/events/jan2026 Play Video Play Video 18:45 "The Endocrine in Neuroendocrine" • Run Yu, MD, Endocrinologist, UCLA •2024 NET Cancer Day Symposium Dr. Run Yu, Endocrinologist from UCLA, discusses "The Endocrine in Neuroendocrine" at the 2024 NET Cancer Day Symposium. Play Video Play Video 01:33:48 LACNETS • "Symptom Management" with Dr. David Metz • Oct 2023 Join LACNETS to hear Neuroendocrinologist, Dr. David Metz from University of Pennsylvania discuss symptom management. The presentation will cover carcinoid syndrome, pancreatic enzymes, bile acid secretion, and short bowel syndrome. He will explain current treatments, supplements, and diets that might be helpful to control NET-related symptoms. For more information, visit LACNETS.org. Play Video Play Video 21:13 13. Managing NET Symptoms & Treatment Side Effects (Dr. Sandy Kotiah) - 2022 LACNETS Conference Dr. Sandy Kotiah addresses the management of #NET symptoms and treatment side effects. Speaker: Sandy Kotiah, MD Medical Oncologist, Mercy Medical 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 05:17 Patient Story: NET Patient shares how she is thriving as a NET patient (LACNETS) NET Patient Cindy shares how she is thriving as a NET patient. November 7, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 04:26 Patient Story: NET Patient shares about symptom management (LACNETS) NET Patient Brent shares about symptom management. June 20, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 06:00 11. Patient Story about Symptom Management (Val) - 2021 LACNETS Virtual Conference NET Patient Val shares her experience with symptom management and NETs. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:02:18 LACNETS - "Pain Management for NETs" Dr. Najmeh Sadoughi Dr. Najmeh Sadoughi "Multidisciplinary Approaches to Pain Management for Neuroendocrine Tumors" Najmeh Sadoughi, MD Board Certified Interventional Pain Specialist LACNETS Patient Education Seminar January 9, 2018 UCLA Los Angeles, California LACNETS is a program by Generate Possibility, a 501(c)(3) non-profit corporation. Los Angeles Carcinoid Neuroendocrine Tumor Society www.LACNETS.org Play Video Play Video 01:38:07 LACNETS Webinar: "Management of Diarrhea in NETs” with Dr. Shirley Paski Management of Diarrhea in NETs” with Dr. Shirley Paski Recorded on October 13th, 2020 Speaker: Shirley Paski, MD, IM/Gastroenterology, Cedars-Sinai Medical Center Learn more here: www.LACNETS.org Audio/Video - www.TVPlive.com Play Video Play Video 49:02 Symptom Management: Diarrhea, Hyperglycemia & Diabetes - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 6:30) Brent, NET Patient "Symptom Management: Diarrhea" (6:30 - 29:05) David C. Metz, MD, Gastroenterology Penn Medicine "Symptom Management: NET-related Hyperglycemia and Diabetes" (29:05 - end of video) Run Yu, MD, PhD , Endocrinology UCLA Health For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 17:19 12. Symptom Management (Dr. Del Rivero) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Jaydira Del Rivero, MD Endocrinologist, Oncologist NIH This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 45:02 "Manejo Sintomatico de los Tumores Neuroedocrinos Funcionales" con Dr. Jaydira Del Rivero "Manejo Sintomatico de los Tumores Neuroedocrinos Funcionales" con Dr. Jaydira Del Rivero Presentadora: Jaydira Del Rivero, MD Endocrinologist, Oncologist; NIH Para obtener más recursos en español, visite www.LACNETS.org/spanish-resources. < Back to Topics Next Topic >

IL13Rα2 CAR T Cell Study for Solid Tumor Cancers << Back Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors IDENTIFIER ( ClinicalTrials.gov ) : NCT04119024 DRUG/TREATMENT : IL13Ralpha2 CAR T Cells PHASE : 1 STATUS : Recruiting at Stanford Medicine, UCLA, and City of Hope SPONSOR : CIRM DESCRIPTION: https://www.youtube.com/watch?v=FgGTrZ6lx1w Dr. Anusha Kalbasi from Stanford discusses the immunotherapy study using IL13Rα2 CAR T cell for the treatment of metastatic solid tumors on March 27, 2024 This clinical trial investigates a novel gene therapy (IL13Ralpha2 CAR T cells) approach for advanced melanoma and other solid tumors. It aims to assess the safety and effectiveness of gene-modified immune cells targeting cancer cells. The trial seeks to determine the safety and potential effectiveness of IL13Ralpha2 CAR T cells in fighting cancer. By evaluating the dose and the IL13Ralpha2 CAR T cells ability to attack cancer cells, researchers at UCLA, Stanford, and City of Hope aim to improve treatment options for advanced cancers. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Christy Sidhu; UCLA = Jonsson Comprehensive Cancer Center EMAIL: PICICenterResearch@mednet.ucla.edu PHONE: 310-206-5087 Principal Investigators: Dr. Antoni Ribas, MD, PhD (UCLA) Dr. Allison Betof Warner, MD, PhD (Stanford Medicine) Dr. Yan Xing, MD, PhD (City of Hope) RESOURCES : Patient Information Sheet

Newly Diagnosed < Back to Topics Play Video Play Video 17:40 2. Understanding Neuroendocrine Cancer: What Should I Know About My Cancer? • Dr. Udhayvir Grewal In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Udhayvir Grewal, GI and neuroendocrine medical oncologist at Winship Cancer Institute of Emory University, presents “Navigating an Understanding of Neuroendocrine Cancer: What Should I Know About My Cancer?” Dr. Grewal explains key concepts that patients and caregivers should understand after a neuroendocrine cancer diagnosis, including grade, stage, differentiation, Ki-67, mitotic index, imaging, somatostatin receptors, hormone production, molecular profiling, and the importance of a specialized multidisciplinary care team. This presentation also discusses the role of CT, MRI, and PET scans; how imaging can affect staging and treatment planning; why molecular testing may help guide personalized therapy; and why expert care and patient advocacy are essential throughout the neuroendocrine cancer journey. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026conference This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment. #NeuroendocrineCancer #NETCancer #NeuroendocrineTumors #NETs #CancerEducation #NCF #PatientConference #CancerDiagnosis #CancerTreatment #CancerSupport #ClinicalTrials Play Video Play Video 01:34:59 Just Diagnosed With Neuroendocrine Cancer? What to Know and Understand • 2026 NCF Event • Apr 23, 26 ABOUT Being newly diagnosed with neuroendocrine cancer (NETs) can feel overwhelming. Many patients find themselves asking, “What exactly is neuroendocrine cancer, and how is it different from other cancers?” This webinar is designed to bring clarity, reassurance, and guidance during one of the most confusing stages of the NET journey. Join Dr. Osama MoSalem, medical oncologist at St. Luke’s in Kansas City, for a clear and compassionate overview of what every newly diagnosed NET patient should know. Dr. MoSalem explains what neuroendocrine cancer is, why it behaves differently from more common cancers, and how its unique features influence diagnosis and treatment. This session walks you through the most important early concepts, including: - Grade and stage: what they mean and why they matter - Key tests and scans used at diagnosis - Treatment pathways, including when to consider surgery, medications, targeted therapies, radioligand therapy, or clinical trials - Essential questions to ask your care team - Practical first steps to help you feel more prepared and empowered Whether you’re newly diagnosed, supporting a loved one, or simply trying to better understand this disease, this webinar provides a solid foundation to help you make informed decisions with greater clarity and confidence. Visit the event page at https://www.ncf.net/events/apr2026 Play Video Play Video 01:37:36 "The Latest in the Management of Functional Neuroendocrine Cancers • Jan, 2026 • Dr. Del Rivero Join this @NCFCancer educational patient event for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), and other hormone-related issues. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. Potential Topics: Functional NET, Hormone-producing, Insulinoma, Gastrinoma, VIPoma, Zollinger-Ellison syndrome (ZES), Carcinoid, Hypoglycemia, Diarrhea, Flushing ABOUT DR. JAYDIRA DEL RIVERO Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. For more information, visit https://www.ncf.net/events/jan2026 Play Video Play Video 17:45 04. NETs 101: NET Terms & Concepts You Need to Know • Bassam Sonbol, MD • Arizona • @NCFCancer ⁩ Play Video Play Video 25:45 "NETS 101" • Jaydira Del Rivero, MD • 2023 NET Cancer Day Symposium @NCFCancer Jaydira Del Rivero, MD • 2023 NET Cancer Day Symposium • Santa Monica, CA Speaker: Jaydira Del Rivero, MD Medical Oncologist Endocrinologist National Cancer Institute, NIH For more information, visit LACNETS.org. Play Video Play Video 35:16 "Understanding NET Diagnosis" with Dr. Chandrasekharan • 2024 #LACNETS Patient Conference 2. "Understanding NET Diagnosis" with #Dr.Chandrasekharan Our 2024 LACNETS Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET) patients and caregivers to deepen your understanding of NETs. Whether you are newly diagnosed or have been living with NET for many years, we encourage you to attend: - Learn from top NET experts from across North America on a range of topics relevant to the NET patient journey. - Topics include work-ups, scans, surgery, carcinoid crisis, liver-directed therapy, PRRT, systemic treatments, treatment sequencing, NET guidelines, and clinical trials. - Gain insight into NET decision-making through the NET tumor board panel discussion. - Hear stories from NET patients and caregivers. - Join virtually, where you can pause, rewind, or replay. - There is no cost to attend. This event is made possible by the generosity of donors and sponsors. #LACNETS #neuroendocrinecancer #clinicaltrials #lungcancer #NETcancer #Letstalkaboutnets For more information, visit LACNETS.org. Play Video Play Video 21:51 NETS 101: Overview of NET Terms & Concepts • Dr. Aman Chauhan • 2023 LACNETS Patient Conference Watch "NETS 101: Overview of NET Terms & Concepts" with Dr. Aman Chauhan. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit, LACNETS.org. Play Video Play Video 15:22 05. NET Surgery: Making Decisions & Preparing for Surgery (Dr. Clarke) - 2022 LACNETS Conference Dr. Callisia Clarke addresses surgery for neuroendocrine cancer including decision-making & preparing for surgery. Presenter: Callisia Clarke, MD Surgical Oncologist Medical College of WI 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 07:50 Patient Story: NET Patient shares about the first year of her NET journey (LACNETS) NET Patient Laurie shares about the first year of her NET journey. November 7, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 01:37:42 LACNETS Webinar: "Sequencing of Neuroendocrine Tumor Treatments" with Dr. Eric Liu LACNETS webinar - “Sequencing of Neuroendocrine Tumor Treatments" Friday, May 24th, 2020 SPEAKER: Dr. Eric Liu, General Surgeon & Neuroendocrine Specialist Rocky Mountain Cancer Center Learn more here: www.LACNETS.org Audio/Video - www.TVPlive.com Play Video Play Video 01:04:39 LACNETS - NET VITALS Webinar - September 6th, 2018 Download NET VITALS here: www.lacnets.org/netvitals NET VITALS Webinar - Question Timing Guide: Introductions: Start - 10:25 Q1. My neuroendocrine tumor (NET) was found: 10:41 Q2. I am a neuroendocrine tumor (NET) patient and my primary (origin) tumor is: 11:05 Q3. My NET has spread (metastasized) to: 11:57 Q4. My Ki-67 index is 14:20 Record-keeping: 14:38 Pathology report example: 17:25 Q5. My neuroendocrine tumor is: 18:15 Q6. My neuroendocrine tumor is: 22:17 Q7. I have symptoms: 23:50 Q8. I have had symptoms for ____ years (if applicable). 23:50 Q9. I have had the following types of imaging, and possess the disk and/or report: 29:30 Q10. I have had the following labs, and possess the report (if applicable): Indicate if abnormal. 32:55 Q11. Surgery to remove primary tumor(s): 38:45 Q12. Surgery to remove metastatic tumor(s): 39:05 Q13. Other surgery 39:40 Q14. Liver-Directed treatment: 40:10 Q15. Somatostatin Analogs (SSA) & Others: 42:48 Q16. Chemotherapy / Biologically-Targeted / Immunotherapy, including Clinical Trials/ PRRT (Peptide Receptor Radionuclide Therapy, i.e. Lutathera®): 44:03 Q17. I am diabetic: 47:50 Q18. ALLERGIES (Medications/Food): 48:05 Q19. FAMILY HISTORY (Specify cancer and/or rare diseases): 48:20 Q20. I have had Genetic Testing: 48:37 Q21. MEDICATIONS/SUPPLEMENTS (including vitamins, digestive enzymes): 49:01 Q22. CURRENT PHYSICIAN(S) & MEDICAL TEAM 49:29 Q23. SOCIAL SUPPORT 50:13 Q&A with the NET VITALS Team 52:23 What is NET Vitals? LACNETS created NET VITALS as a quick snapshot of the most important questions for patients and healthcare professionals to know about neuroendocrine cancer. NET VITALS is a 20-question tool designed to highlight the vitals of NET cancer, all in one document. This allows the physician and patient to more easily communicate with all of the basics in one place. Webinar Leaders: Giovanna Joyce Imbesi, MBA, Executive Director, LACNETS Lisa Yen, NP, NBC-HWC, Program Director, LACNETS Dan Li, MD, Medical Oncologist, City of Hope Josh Mailman, MBA, President, NorCal CarciNET Learn more here: https://www.lacnets.org/lacnets-blog/netvitals Play Video Play Video 20:22 "Qué esperar de una consulta de expertos de NET" con Dr. Heloisa Soares (LACNETS) "Qué esperar de una consulta de expertos de NET" con Dr. Heloisa Soares (LACNETS) Presentadora: Heloisa Soares, MD, PhD Medical Oncologist; Huntsman Cancer Institute Para obtener más recursos en español, visite www.LACNETS.org. Play Video Play Video 30:23 04. What to Expect with a NET Expert Consultation (Dr. Soares) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Heloisa Soares, MD, PhD Medical Oncologist Huntsman Cancer Institute This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 42:50 Finding a NET Expert + Surgery for NETs - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: LACNETS Conference Welcome (0:00 - 5:44) Lindsey Jeu De Vine, Director of Communications, LACNETS Lisa Yen, NBC-HWC, Program Director, LACNETS "Finding a NET Expert" (5:44 - 22:25) Cindy Lovelace , Executive Director Healing NET Foundation "Surgery for NETs" (22:25 - end of video) Alexandra Gangi, MD , Surgical Oncology Cedars-Sinai Medical Center For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 43:19 "NETs 101" with Medical Oncologist Dr. Sandy Kotiah of Mercy Medical Medical oncologist and NET expert Dr. Kotiah covers what to expect during your first visit with your medical oncologist – plus labs, scans, and prognosis. Speaker: Sandy D. Kotiah, MD Medical Oncologist, Hematologist Mercy Medical To learn more about LACNETS, visit www.LACNETS.org. < Back to Topics Next Topic >

Diarrhea < Back to Topics Play Video Play Video 19:19 3. Navigating Scans • Dr. Delphine Chen, Fred Hutch Cancer Center • Neuroendocrine Cancer Foundation In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Delphine Chen, nuclear medicine physician at Fred Hutch Cancer Center and the University of Washington, presents “Navigating Scans.” Dr. Chen explains how imaging is used in the diagnosis, staging, monitoring, and treatment planning of neuroendocrine tumors. She discusses commonly used imaging tools, including CT, MRI, and Dotatate PET, and explains why different scans may be recommended depending on the location and biology of the tumor. This presentation covers the role of multiphase contrast CT and MRI in identifying liver metastases, how Dotatate PET can help detect well-differentiated neuroendocrine tumors, and how imaging may be used to assess eligibility for peptide receptor radionuclide therapy (PRRT). Dr. Chen also discusses surveillance imaging, treatment monitoring, scan frequency, and the importance of interpreting imaging results within the context of each patient’s care plan. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026conference This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment. #NeuroendocrineCancer #NeuroendocrineTumors #NETCancer #NETs #DotatatePET #CancerImaging #CTScan #MRI #PRRT #NCF #PatientConference #CancerEducation Play Video Play Video 14:53 4. What Matters About Scans? • Nadine Mallak, MD • @NCFCancer "What Matters About Scans" 2025 Neuroendocrine Cancer Foundation Annual Patient Conference Nadine Mallak, MD Radiologist & Nuclear Medicine Oregon Health & Science University @NCFCancer Play Video Play Video 23:47 "Understanding NET Scans" with Dr. Nadine Mallak • 2024 LACNETS NET Patient Conference 3) Understanding NET Scans • 2024 Neuroendocrine Tumor Patient Conference Our 2024 LACNETS Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET) patients and caregivers to deepen your understanding of NETs. Whether you are newly diagnosed or have been living with NET for many years, we encourage you to attend: - Learn from top NET experts from across North America on a range of topics relevant to the NET patient journey. - Topics include work-ups, scans, surgery, carcinoid crisis, liver-directed therapy, PRRT, systemic treatments, treatment sequencing, NET guidelines, and clinical trials. - Gain insight into NET decision-making through the NET tumor board panel discussion. - Hear stories from NET patients and caregivers. - Join virtually, where you can pause, rewind, or replay. - There is no cost to attend. This event is made possible by the generosity of donors and sponsors. #LACNETS #neuroendocrinecancer #clinicaltrials #lungcancer #NETcancer #Letstalkaboutnets For more information, visit LACNETS.org. Play Video Play Video 19:08 The Latest in NET Imaging • Dr. Nadine Mallak • 2023 LACNETS Patient Education Conference Watch "The Latest in NET Imaging" with Dr. Nadine Mallak. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 16:32 10. The Latest in NET Imaging & PRRT (Dr. Thomas Hope) Radiologist Dr. Thomas Hope addresses the latest in NET imaging and PRRT. Speaker: Thomas Hope, MD Radiologist, UCSF 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:33:28 LACNETS Webinar: "NET Imaging: Scans & Reports" with NET Radiologist Dr. Gary Ulaner NET radiologist Dr. Gary Ulaner from Hoag Family Cancer Institute explains different scans used for NET imaging and how to understand your radiology reports. This webinar includes a presentation and live Q&A. Additional NET imaging resources can be found here: lacnets.org/imaging To learn more about LACNETS, visit www.LACNETS.org. < Back to Topics Next Topic >

The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. Be sure to subscribe to our podcast to receive notifications when new episodes are released! 2026 2025 2024 2023 2022 2021 2026 2026 LISTEN LISTEN LISTEN 2025 2025 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2024 2024 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2023 2023 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2022 2022 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2021 2021 LISTEN LISTEN LISTEN LISTEN LISTEN

<< Back Pancreatic NET (PNET) Insulinoma upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism PRRT/RLT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Pb-212 VMT Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Lu-177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu-177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Triapine (GEP-NETs) Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE + Sunitinib in PNETs COMPOSE (GEP-NETS) ComPareNET Lu-177 vs CAPTEM in PNETs Lu-177 DOTATATE vs Everolimus in Lung NETs NETTER-P: Lutathera in Adolescent Patients Oral Treatment SWOG S2104: Adjuvant CAPTEM for High Risk pNET Belzutifan/MK-6482 in PNET + PPGL + VHL CDK4/6 Abemaciclib Other Trials Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IL13Rα2 CAR T Cell Study for Solid Tumor Cancers SORENTO™: Subcutaneous Octreotide for GEP-NETs Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) SORENTO™: Subcutaneous Octreotide for GEP-NETs STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC << Back Ph I/II Trial of Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC CLINICALTRIALS.GOV IDENTIFIER: NCT03647163 Drug/Treatment: VSV-IFNβ-NIS and Pembrolizumab PHASE: I/II STATUS: Recruiting Sponsor: Vyriad, Inc. Collaborator: Mayo Clinic https://www.youtube.com/watch?v=Pw8oSIOt0og Dr. Heloisa Soares Discusses Systemic VSV-IFNβ-NIS and Pembrolizumab DESCRIPTION: Vyriad is sponsoring the safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design. The expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion of the trial will be used for the expansion portion. The study has been conducted with a dose of 1.7 × 1010 as the recommended phase II dose in an expansion cohort of 10 patients with NSCLC. However, current data suggests that VSV-IFNβ-NIS doses of up to 1.7 × 1011 is safe and likely more efficacious. Thus, this study will test a second VSV-IFNβ-NIS dose level, 1.0x1011 TCID50. A safety assessment will be carried out after 3 patients are enrolled. If this dose schedule is well tolerated and virus PK are not negatively impacted, both the NSCLC and NEC expansion cohorts will open using this dose schedule. If 2 of the first 3 patients or 2 of the first 6 patients experience a DLT, the dose will be de-escalated to 5 x 1010. The safety run-in/dose escalation portion of this study is expected to require a minimum of 3 patients and a maximum of 18 patients (6 patients per dose level). The expansion portion of this study is expected to require a minimum of 10 per cohort. The NSCLC and NEC patients enrolled at the identified optimal dose in the dose escalation cohort would be included in the dose expansion cohort if they are evaluable for the primary endpoint in the expansion portion (4 dose escalation patients at the optimal dose are expected to roll over to the expansion). Therefore, the overall sample size details will be a maximum of 40 patients. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Jennifer Boughton EMAIL: JBoughton@vyriad.com PHONE: 908-553-3135 Shruthi Naik, PhD EMAIL: snaik@vyriad.com PRINCIPAL INVESTIGATOR: Julian R. Molina, MD, PhD Mayo Clinic

Lung NET < Back to Topics Play Video Play Video 01:28:05 "Large Cell Neuroendocrine Carcinoma & Small Cell Lung Cancer" • Session B • LACNETS • Dec 10, 2024 This is a 2-session comprehensive guide to lung neuroendocrine cancers. Session A covers Typical Carcinoids and Atypical Carcinoids. Watch Session A here: https://youtu.be/owZRDf3ISM4 Session B covers Large Cell Neuroendocrine Carcinoma and Small Cell Lung Cancer. ABOUT AMAN CHAUHAN, M.D. Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. For more information, visit LACNETS.org. Play Video Play Video 01:33:36 "Typical Carcinoid & Atypical Carcinoid" • Session A • LACNETS Event • Dec 10, 2024 This is a 2-session comprehensive guide to lung neuroendocrine cancers. Session A covers Typical Carcinoids and Atypical Carcinoids. Session B covers Large Cell Neuroendocrine Carcinoma and Small Cell Lung Cancer. Watch Session B here: https://youtu.be/LxXdXMKpaCo ABOUT AMAN CHAUHAN, M.D. Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. For more information, visit LACNETS.org. Play Video Play Video 03:40 NET Patient Dorinda Shares her Journey - LACNETS Hear Dorinda's story Play Video Play Video 44:15 Episode 26 - What to Know About Lung NETs ABOUT THIS EPISODE What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon. MEET DR. VINEETH K. SUKRITHAN Dr. Vineeth Sukrithan is a medical oncologist who specializes in the study and treatment of neuroendocrine cancer, thyroid cancer and adrenocortical cancer. He utilizes traditional chemotherapy, molecularly targeted oral medications, novel immunotherapy and peptide-receptor radiotherapies in the treatment of these unique cancers. As a comprehensive cancer center, the OSUCCC – James has unrivaled experience and expertise in the treatment of neuroendocrine, thyroid and adrenal tumors. Their world-renowned faculty are leaders in the study and treatments of these rare cancers, and as such, they are able to provide their patients with options beyond standard therapies that may not be available anywhere else. The strong focus on translational research at The James means that the treatment breakthroughs of tomorrow are being discovered in their laboratories today. Dr. Sukrithan is part of a tight-knit team of surgical oncologists, radiation oncologists and interventional radiologists who work together to provide cutting-edge care for our patients with neuroendocrine tumors. In addition to his clinical work, Dr. Sukrithan is a member of the Translational Therapeutics Program at the OSUCCC – James and the co-director of the Adrenal Tumor Clinic. He was recently selected to lead an externally funded effort through the International Thyroid Oncology Group to operationalize a multi-institutional registry database for patients with medullary thyroid cancer. Dr. Sukrithan also serves as an assistant professor in the Division of Medical Oncology at The Ohio State University and has completed postdoctoral fellowships in clinical research at Johns Hopkins University. His research has been published in numerous peer-reviewed journals, including Cancer Research, American Journal of Clinical Oncology and Clinical Lung Cancer. As every individual’s cancer is molecularly unique in countless ways, Dr. Sukrithan believes in tailoring therapies to the individual with the precision made available through cutting-edge scientific research. He feels it is a privilege to make a difference in the lives of patients as we work together to achieve a cancer-free world. TOP 10 QUESTIONS 1. What are lung NETs? Where are they located? 2. How are lung NETs found? What are the symptoms of a lung NET? 3. How is lung NETs different (or similar) to what is commonly referred to as “lung cancer”? 4. How is it different or similar to DIPNECH? Do all lung NET patients have DIPNECH and do all DIPNECH patients have lung NET? 5. How is lung NET similar or different from other types of NETs? What makes it unique? 6. What types of labs, scans, or testing is done to determine if someone has a lung NET and DIPNECH? What is the best type of scan for lung NETs? 7. How do you decide if the lung NET can be surgically removed? What type of surgeon would make that determination and when in their patient journey might they see a surgeon? 8. How are lung NETs treated medically (or nonsurgically)? How are the treatments different from other NETs? How are treatments sequenced? 9. How are lung NETs monitored? What types of blood work, tests and scans should be done and how often should they be done? 10. What advances in the field or clinical trials should we be aware of? What new advances or treatments in the pipeline for lung NETs are you most excited about? Play Video Play Video 01:28:16 LACNETS Webinar: "Update on Lung NETs" with Dr. Sukhmani Padda What types of lung NETs are there? How is lung NETs treated? Lung NET specialist Dr. Sukhmani Padda of Cedar-Sinai addresses these questions and gives an update on lung NETs. Lung NETs is a less common type of NET so we wanted to dedicate a webinar to this topic. *This webinar was recorded on August 25, 2022. Speaker: Sukhmani Padda, MD Lung NET Specialist, Cedars-Sinai Additional lung NETs resources can be found here: www.lacnets.org/lung-net-resources To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 01:40:32 LACNETS Webinar: "Focus on Lung Carcinoid Tumors" with Dr. Robert Ramirez Join LACNETS and Lung NET expert Dr. Robert Ramirez of Vanderbilt University Medical Center, for his presentation and Q&A on, "Focus on Lung Carcinoid Tumors." Download the presentation slides from this webinar here: bit.ly/3l1BuyJ Speaker: Robert Ramirez, MD Associate Professor of Medicine Vanderbilt University Medical Center For more information on LACNETS, visit www.LACNETS.org. Play Video Play Video 01:17:15 "Systemic Therapy: GI, Lung, PNETS & Unknown Primary" 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 7:03) Eric, NET Patient "Systemic Therapy: GI NETs" (7:03 - 28:13) Dan Li, MD , Medical Oncology City of Hope "Systemic Therapy: Lung NETs" (28:13 - 52:08) Robert Ramirez, DO, FACP, Neuroendocrine & Thoracic Oncology Ochsner Medical Center "Systemic Therapy: PNETs and NETs of Unknown Primary" (52:08 - end of video) Andrew Hendifar, MD, Medical Oncology Cedars-Sinai Medical Center For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. < Back to Topics Next Topic >

Explore neuroendocrine tumor imaging resources like diagnostic scans, disease monitoring, staging, and imaging technologies used throughout NET care. Neuroendocrine Tumor Imaging Resources PODCAST Confused about scans? NET expert Dr. Gary Ulaner answers the top 10 questions about imaging for NETs. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner explains different scans used in NET imaging including functional imaging scans such as Gallium-68 DOTATATE, Copper-64 DOTATATE, and FDG PET scans and anatomical scans such as MRI and CT scans. He addresses common questions about radiation safety, contrasts, and SUV. Listen Here EDUCATIONAL WEBINARS NET Imaging NET Imaging Play Video Share Whole Channel This Video Facebook Twitter Pinterest Tumblr Copy Link Link Copied Now Playing 3. Navigating Scans • Dr. Delphine Chen, Fred Hutch Cancer Center • Neuroendocrine Cancer Foundation 19:19 Play Video Now Playing 4. What Matters About Scans? • Nadine Mallak, MD • @NCFCancer 14:53 Play Video Now Playing "Understanding NET Scans" with Dr. Nadine Mallak • 2024 LACNETS NET Patient Conference 23:47 Play Video ADDITIONAL IMAGING RESOURCES Detectnet Patient Brochure by Curium Detectnet is used with a PET scan to help diagnose possible NETs A Guide to Understanding Neuroendocrine Tumors (NETs) and the Role of Imaging NANETS NET GUIDELINES 2017 (Joint with SNMMI) Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

Alpha PRRT with Pb-212 VMT << Back Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT) IDENTIFIER ( ClinicalTrials.gov ) : NCT05636618 DRUG/TREATMENT : Alpha PRRT with 212Pb VMT PHASE : 1 / 2A STATUS : Recruiting SPONSOR : Perspective Therapeutics DESCRIPTION: https://www.youtube.com/watch?v=kOmdkMwoceQ June 2024: Dr. Aman Chauhan discusses the Alpha PRRT with Pb-212 VMT study. Perspective Therapeutics is sponsoring a phase 1 / 2A prospective, multi-center open-label dose escalation, dose expansion study of [212Pb]VMT01 in up to 52 adult subjects with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapy (PRRT). During phase 1, there is a dose escalation period testing up to 4 escalating radioactivity dose cohorts of up to 8 subjects (administered at approximately 8-week intervals) at the assigned cohort radioactivity dose. Phase 1 studies the side effects, safety, and dosimetry. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Markus Puhlmann, MD, MBA at Perspective Therapeutics EMAIL: mpuhlmann@perspectivetherapeutics.com PHONE: (319) 665-2150